EC grants marketing authorisation for cystic fibrosis drug Orkambi
20 November 2015 | By Victoria White
Orkambi (lumacaftor/ivacaftor), authorised for use in patients who have two copies of the F508del mutation, is the first medicine to treat the underlying cause of cystic fibrosis...